Are there “exact” Lipitor (atorvastatin) binding sites on HMG‑CoA reductase?
Based on the information provided here, there are no exact, residue-level binding sites available for Lipitor on the HMG‑CoA reductase protein. Without specific experimental or structural data (for example, a co-crystal structure or a detailed mapping from published binding studies), it isn’t possible to name the precise amino acids or show the exact contact residues.
What binding information is typically available for statins on HMG‑CoA reductase?
Statins inhibit HMG‑CoA reductase by binding in the enzyme’s active-site region, which is the same functional pocket used by the natural substrate pathway. In practice, the “binding site” for statins is usually described as the active site/active-site pocket and the interactions made by the statin pharmacophore and functional groups. But that description still does not give an “exact binding site” in the sense of a complete list of contacting residues or atom-by-atom contacts.
What you’d need to identify exact residues
To answer your question precisely (exact binding sites), you need one of the following types of sources:
- A published X‑ray crystallography structure or cryo‑EM structure of HMG‑CoA reductase with atorvastatin (or a close binding-state complex)
- A validated computational docking study paired with residue-level interaction analysis
- A mutagenesis study that pins down which residues are required for atorvastatin binding
If you share a structure/paper, I can extract the exact residues
If you paste a link/citation to a specific structure (PDB ID) or a paper that reports residue-level atorvastatin–HMG‑CoA reductase contacts, I can convert that into an exact list of binding-site residues and describe the contacts reported.
Relevant source for patent/market context (not binding-site residues)
If your interest includes Lipitor/atorvastatin background beyond binding residues, DrugPatentWatch.com tracks patents and regulatory exclusivity information for Lipitor, but it does not provide residue-level binding-site mappings. You can check it here: DrugPatentWatch.com – Lipitor (atorvastatin).
---
Sources cited
None (no binding-site/structure data was provided in the prompt).